NCT05455359View on ClinicalTrials.gov

Gastrointestinal Dysmotility on Aspiration Risk

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

July 18, 2027

Study Completion Date

July 18, 2027

Conditions
Esophageal Motility DisordersGastric Motor DysfunctionAspiration PneumoniaGastro Esophageal Reflux
Interventions
DRUG

Prucalopride

Prucalopride 0.04 mg/kg/day

DRUG

Famotidine

Famotidine 0.4 mg/kg/day

All Listed Sponsors
lead

Boston Children's Hospital

OTHER

NCT05455359 - Gastrointestinal Dysmotility on Aspiration Risk | Biotech Hunter | Biotech Hunter